PROTEUS trial heralds perioperative therapy for prostate cancer

The PROTEUS trial presents promising results in the field of prostate cancer treatment. It focuses on perioperative therapy, which is administered before and/or after surgical intervention. Specifically, it involves a combination of androgen-deprivation therapy (ADT) with the drug apalutamide. This combination could represent a new treatment option. It is intended for patients with high-risk, localized prostate cancer. The aim is to improve treatment outcomes for this patient group. If its efficacy is confirmed, this therapy could change standard procedures. It represents a significant advancement in the search for more effective methods to combat this disease.